Sheng Xu, PhD

BeOne Medicines Ltd, China (People's Republic)

Poster(s):

• 1909 - A Network Meta-Analysis (NMA) of Efficacy of Zanubrutinib versus Fixed-Duration Acalabrutinib Plus Venetoclax in Treatment-naïve (TN) Chronic Lymphocytic Leukemia (CLL)

• 1910 - Comparative Efficacy of Zanubrutinib (ZANU) versus Fixed-Duration Acalabrutinib Plus Venetoclax (AV) for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL): A Matching-Adjusted Indirect Comparison (MAIC)